title: Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccine.
abstract: BACKGROUND
  Administration of two doses of hepatitis A (HA) vaccine to children > or = 2 years of age has been shown to be protective. The present study assessed whether HA vaccine can be administered as early as 6 months of age and whether it can be administered concomitantly with a hexavalent (HV) vaccine at this age.
  
  
  METHODS
  In an open label, randomized, parallel group study, the liquid HV vaccine (HEXAVAC) (diphtheria, tetanus, 2-component acellular pertussis, inactivated poliomyelitis vaccine, Haemophilus influenzae type b conjugated to tetanus protein and hepatitis B) was administered at 2, 4, 6, and 12 months of age to all children. HA vaccine (VAQTA) was given at 7 and 13 months in the separate administration group (Group 1) and at 6 and 12 months in the concomitant administration group (Group 2). Serum samples were obtained at 2, 7, 12, and 14 months in Group 1 and at 2, 7, 12, and 13 months in Group 2. The primary immunogenicity outcomes were the seroconversion rates for HA 1 month after the second dose of HA vaccine in initially seronegative subjects, and the seroconversion rates for each HV antigen 1 month after the third dose of the HV vaccine (both at 7 months of age).
  
  
  RESULTS
  HA seropositivity rates 1 month after the second dose were 100% in both groups, regardless of initial serostatus. The responses to each HV antigen 1 month after the third dose were similar in both groups. The vaccines were generally well tolerated in both groups regardless of vaccine(s) administered.
  
  
  CONCLUSIONS
  A schedule of two doses of HA vaccine, 6 months apart beginning at 6 months of age is highly immunogenic and well tolerated when administered alone or concomitantly with HV vaccine at 6 and 12 months of age.
authors: University Children's Hospital, Ludwig-Maximilians-University, Munich, Germany.
authors: S
authors: S
authors: Stojanov
authors: J G
authors: JG
authors: Liese
authors: B H
authors: BH
authors: Belohradsky
authors: C
authors: C
authors: Vandermeulen
authors: K
authors: K
authors: Hoppenbrouwers
authors: M
authors: M
authors: Van der Wielen
authors: P
authors: P
authors: Van Damme
authors: B
authors: B
authors: Georges
authors: M
authors: M
authors: Dupuy
authors: M
authors: M
authors: Scemama
authors: M
authors: M
authors: Watson
authors: A
authors: A
authors: Fiquet
authors: J E
authors: JE
authors: Stek
authors: G T
authors: GT
authors: Golm
authors: F P
authors: FP
authors: Schödel
authors: B J
authors: BJ
authors: Kuter
mesh_terms: D000367:Age Factors; D002675:Child, Preschool; D005260:Female; D035922:Hepatitis A Antibodies / Q000097:blood; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D017778:Vaccines, Combined